X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
moderately emetogenic chemotherapy (488) 488
humans (370) 370
oncology (340) 340
double-blind (333) 333
vomiting - chemically induced (275) 275
nausea (258) 258
index medicus (254) 254
chemotherapy (250) 250
nausea - chemically induced (248) 248
antiemetics - therapeutic use (227) 227
antineoplastic agents - adverse effects (227) 227
prevention (215) 215
vomiting - prevention & control (213) 213
cancer (202) 202
female (200) 200
nausea - prevention & control (193) 193
vomiting (181) 181
middle aged (175) 175
palonosetron (164) 164
male (156) 156
dexamethasone (155) 155
adult (142) 142
ondansetron (137) 137
placebo-controlled trial (131) 131
aged (130) 130
phase-iii (127) 127
aprepitant (126) 126
chemotherapy-induced nausea and vomiting (120) 120
vomiting - drug therapy (113) 113
chemotherapy-induced nausea (111) 111
cisplatin-induced emesis (111) 111
health care sciences & services (111) 111
antiemetics (110) 110
medicine & public health (108) 108
neoplasms - drug therapy (106) 106
pharmacology & pharmacy (100) 100
rehabilitation (100) 100
nausea - drug therapy (96) 96
high-dose cisplatin (93) 93
induced nausea (90) 90
antiemetics - administration & dosage (87) 87
efficacy (85) 85
quality-of-life (84) 84
nursing (81) 81
emesis (77) 77
treatment outcome (77) 77
antineoplastic combined chemotherapy protocols - adverse effects (76) 76
pain medicine (69) 69
rehabilitation medicine (69) 69
isoquinolines - therapeutic use (68) 68
quinuclidines - therapeutic use (68) 68
dexamethasone - therapeutic use (66) 66
drug therapy, combination (66) 66
antiemetics - adverse effects (63) 63
delayed emesis (63) 63
granisetron (63) 63
receptor antagonist (63) 63
guideline update (61) 61
quality of life (60) 60
serotonin antagonists - therapeutic use (60) 60
care and treatment (58) 58
morpholines - therapeutic use (58) 58
antineoplastic agents - therapeutic use (57) 57
gastrointestinal agents (57) 57
nursing management/nursing research (55) 55
trial (53) 53
cisplatin (52) 52
drug therapy (51) 51
cinv (50) 50
5-ht3 receptor antagonist (49) 49
antiemetic efficacy (48) 48
breast-cancer (47) 47
dexamethasone - administration & dosage (47) 47
research (47) 47
complications and side effects (46) 46
prospective studies (46) 46
risk factors (46) 46
antineoplastic combined chemotherapy protocols - therapeutic use (45) 45
antiemetic therapy (44) 44
isoquinolines - administration & dosage (44) 44
quinuclidines - administration & dosage (44) 44
5-ht (43) 43
analysis (43) 43
double-blind method (42) 42
health aspects (42) 42
dosage and administration (41) 41
aged, 80 and over (39) 39
antagonist aprepitant (39) 39
antiemetic (39) 39
cancer-chemotherapy (39) 39
clinical trials (39) 39
induced emesis (39) 39
intravenous ondansetron (38) 38
prophylaxis (38) 38
5-ht3 receptor antagonists (37) 37
neurokinin-1 receptor antagonists (37) 37
antiemetics - pharmacology (36) 36
cancer patients (36) 36
delayed nausea (36) 36
high-dose metoclopramide (34) 34
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
FUTURE ONCOLOGY, ISSN 1479-6694, 03/2019, Volume 15, Issue 7, pp. 753 - 762
Journal Article
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 4/2010, Volume 18, Issue 4, pp. 423 - 431
Aprepitant was shown previously to be effective for prevention of chemotherapy-induced nausea and vomiting (CINV) with moderately emetogenic chemotherapy (MEC)... 
Aprepitant | CINV | Pain Medicine | Rehabilitation Medicine | Nursing | Medicine & Public Health | Moderately emetogenic chemotherapy | Oncology | NK1 antagonist | MEC | Nausea and vomiting | Nursing Management/Nursing Research | ORAL NEUROKININ-1 ANTAGONIST | DEXAMETHASONE | ANTIEMETICS | CANCER | CISPLATIN | ONCOLOGY | HEALTH CARE SCIENCES & SERVICES | REHABILITATION | PLACEBO-CONTROLLED TRIAL | RECEPTOR ANTAGONIST APREPITANT | Prospective Studies | Nausea - chemically induced | Humans | Middle Aged | Antiemetics - administration & dosage | Dexamethasone - adverse effects | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - adverse effects | Antiemetics - therapeutic use | Adult | Antiemetics - adverse effects | Female | Drug Therapy, Combination | Vomiting - prevention & control | Morpholines - adverse effects | Morpholines - therapeutic use | Dexamethasone - administration & dosage | Double-Blind Method | Morpholines - administration & dosage | Ondansetron - administration & dosage | Treatment Outcome | Neoplasms - drug therapy | Nausea - prevention & control | Vomiting - chemically induced | Dexamethasone - therapeutic use | Ondansetron - therapeutic use | Aged | Ondansetron - adverse effects | Prevention | Cyclophosphamide | Anthracyclines | Chemotherapy | Dexamethasone | Clinical trials | Nausea | Research | Toy industry | Tumors | Cancer | Breast cancer | Preventive medicine | Vomiting
Journal Article
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 9/2015, Volume 23, Issue 9, pp. 2833 - 2840
Journal Article
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 11/2018, Volume 26, Issue 11, pp. 3773 - 3780
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 8/2011, Volume 19, Issue 8, pp. 1217 - 1225
A phase III trial assessed the efficacy of palonosetron plus dexamethasone given once in preventing acute and delayed chemotherapy-induced nausea and vomiting... 
Pain Medicine | Nursing | Rehabilitation Medicine | Dexamethasone | Medicine & Public Health | Vomiting | Moderately emetogenic chemotherapy | Oncology | Nausea | Serotonin antagonists | Nursing Management/Nursing Research | Palonosetron | CANCER-CHEMOTHERAPY | EFFICACY | DELAYED EMESIS | APREPITANT | REGIMEN | ONCOLOGY | 5-HT3 RECEPTOR | TOLERABILITY | HEALTH CARE SCIENCES & SERVICES | DOUBLE-BLIND | REHABILITATION | Multivariate Analysis | Confidence Intervals | Serotonin Antagonists - administration & dosage | Nausea - chemically induced | Health Status Indicators | Humans | Middle Aged | Male | Quinuclidines - administration & dosage | Anthracyclines - administration & dosage | Quinuclidines - therapeutic use | Time Factors | Antineoplastic Agents, Hormonal - therapeutic use | Drug-Related Side Effects and Adverse Reactions | Female | Drug Therapy, Combination | Nausea - drug therapy | Dexamethasone - administration & dosage | Risk Assessment | Antineoplastic Agents, Hormonal - administration & dosage | Serotonin Antagonists - therapeutic use | Vomiting - drug therapy | Chi-Square Distribution | Vomiting - chemically induced | Dexamethasone - therapeutic use | Isoquinolines - therapeutic use | Aged | Anthracyclines - therapeutic use | Isoquinolines - administration & dosage | Chemotherapy | Gastrointestinal agents | Clinical trials | Toy industry | Cancer | Neurotransmitters | Drug therapy | Clinical outcomes | Original
Journal Article
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, ISSN 0031-6903, 2018, Volume 138, Issue 8, pp. 1095 - 1101
Journal Article
Journal Article
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 5/2013, Volume 21, Issue 5, pp. 1453 - 1460
Palonosetron (Aloxi®, Onicit®) is a pharmacologically unique 5-HT3 receptor antagonist (RA) approved as a single IV injection for the prevention of nausea and... 
Pain Medicine | Nursing | Rehabilitation Medicine | Medicine & Public Health | 5-Ht 3 receptor antagonist | Moderately emetogenic chemotherapy | Oncology | Nursing Management/Nursing Research | Palonosetron | Chemotherapy-induced nausea and vomiting | 5-Ht | receptor antagonist | ONCOLOGY | CONSENSUS CONFERENCE | HEALTH CARE SCIENCES & SERVICES | 5-Ht receptor antagonist | REHABILITATION | EMESIS | 5-HT3 | Serotonin Antagonists - administration & dosage | Injections, Intravenous | Nausea - chemically induced | Humans | Middle Aged | Antiemetics - administration & dosage | Male | Antineoplastic Agents - therapeutic use | Quinuclidines - administration & dosage | Dose-Response Relationship, Drug | Quinuclidines - therapeutic use | Antineoplastic Agents - adverse effects | Antiemetics - therapeutic use | Adult | Female | Drug Therapy, Combination | Vomiting - prevention & control | Dexamethasone - administration & dosage | Double-Blind Method | Administration, Oral | Serotonin Antagonists - therapeutic use | Treatment Outcome | Neoplasms - drug therapy | Nausea - prevention & control | Vomiting - chemically induced | Dexamethasone - therapeutic use | Isoquinolines - therapeutic use | Aged | Isoquinolines - administration & dosage | Complications and side effects | Chemotherapy | Dexamethasone | Gastrointestinal agents | Clinical trials | Product development | Nausea | Comparative analysis | Cancer | Comparative studies | Drug delivery systems | Preventive medicine | Vomiting | 5-Ht3 receptor antagonist | Original
Journal Article